← All indications
Prediabetic State
The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).
Drugs by status
Phase 4 trials (32)
- metformin
- vitamin d3
- berberine
- mirabegron
- tadalafil
- exenatide
- alpha-lipoic acid
- empagliflozin
- liraglutide
- hydroxychloroquine
- pitavastatin
- Menatetrenone
- bromocriptine
- atorvastatin
- linagliptin
- saxagliptin
- valsartan
- pravastatin
- sitagliptin
- semaglutide
- exendin (9-39)
- xuezhikang
- brown seaweed
- curcumin
- pioglitazone
- multivitamins
- sacubitril
- dapagliflozin
- pyridoxine
- starch
- +2 more
Phase 3 trials (24)
- roflumilast
- simvastatin
- melatonin
- allopurinol
- phentermine
- colesevelam
- chromium tripicolinate
- ethanol
- insulin glargine
- indocyanine green
- magnesium oxide
- topiramate
- pramlintide
- rimonabant
- vildagliptin
- bifidobacterium longum
- biotin
- totum-63
- amino acids
- ivy gourd fruit extract
- gymnema sylvestre leaf extract
- fennugreek
- tea
- sodium chloride
Phase 2 trials (28)
- pegylated arginine deiminase
- alum-gad
- bti320
- canakinumab
- gsk2256294
- menaquinone
- diamyd
- salsalate
- tang ning tongluo
- cenicriviroc
- glucose
- vancomycin
- apple
- human fecal microbiota
- chromium
- walnut
- losartan
- bazedoxifene
- chloroquine
- palm oil
- hydrochlorothiazide
- clindamycin
- anakinra
- neomycin
- dextrose
- 18f-mk6240
- conjugated estrogen
- abscisic acid
Phase 1 trials (19)
Other trials (127)
- ezetimibe
- 68ga-exendin
- sucrose
- acetylcysteine
- urea
- beetroot juice
- cinnamon
- cocoa bean
- copper
- egg
- enalapril
- vitis vinifera
- fiber
- linseed oil
- ginger
- ginseng
- glimepiride
- hydroxytyrosol
- icosapent ethyl
- inulin
- whey protein
- ketone
- l-arabinose
- leucine
- mulberry leaf extract
- niacin
- nondigestible oligosaccharide
- vitamin c
- olmesartan
- beta-glucans
- +97 more
Organizations
Organization Involved with Phase 4 Indications (52)
- Amylin
- Daiichi Sankyo
- AstraZeneca
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Kyunghee University Medical Center
- Hospital General de México Dr. Eduardo Liceaga
- Maastricht University
- Ajou University
- University of Pittsburgh
- American Heart Association
- Chinese Medical Association
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Korea University
- Kyung Hee University
- Ohio State University
- Pauls Stradins Clinical University Hospital
- Postgraduate Institute of Medical Education and Research
- Seoul National University
- Shandong Provincial Hospital
- Srinakharinwirot University
- Universidad de Guanajuato
- University of Dundee
- University of Exeter
- University of Guadalajara
- University of Kentucky
- University of Padova
- University of Toronto
- University of Bristol
- Wroclaw Medical University
- +22 more
Organization Involved with Phase 3 Indications (29)
- Novo Nordisk
- Sanofi
- Novartis
- GlaxoSmithKline
- Hamad Medical Corporation
- Institut Pasteur
- Valbiotis
- Dexa Medica Group
- Harvard University
- Emory University
- University of Washington
- National Cheng Kung University
- RISE Study Group
- Stanford University
- Unidad de Investigacion Medica en Epidemiologia Clinica
- University of Florida
- University of New Mexico
- University of California, Los Angeles
- University of Chicago
- PreEmptive Meds, Pvt. Ltd
- University of Minnesota
- UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France
- Biofortis
- Padang Hospital
- National Medical Centre Siglo XXI Mexican Institute for Social Security
- Ben Gurion University
- Fondo para el Fomento a la Investigacion Medica
- People's Liberation Army of China
- Pennington Biomedical Research Center
Organization Involved with Phase 2 Indications (44)
- Merck
- Araim Pharmaceuticals, Inc.
- Bayer
- Boston Therapeutics
- Resverlogix Corp
- Tobira Therapeutics, Inc.
- National Center for Complementary and Integrative Health (NCCIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute on Aging (NIA)
- Region Skane
- Augusta University
- Clinical Research Centre, Malaysia
- Florida State University
- Lund University
- McGill University
- Monash University
- Oregon Health and Science University
- Rutgers University
- Tufts University
- University of Iowa
- University of Pisa
- University of Science Malaysia
- University of South Florida
- Chinese University of Hong Kong
- Colorado State University
- Columbia University
- University of California, San Francisco
- University of Cincinnati
- University of Copenhagen
- University of Vienna
- +14 more
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (110)
- Merck Serono
- DSM
- Microbiome Therapeutics
- NuSirt Biopharma
- Vedic Lifesciences Pvt. Ltd.
- innoVactiv Inc.
- Boehringer Ingelheim
- Olive Lifesciences Pvt Ltd
- Diabetes Foundation, India
- National Center for Research Resources (NCRR)
- National Nutrition and Food Technology Institute
- United States Air Force
- United States Department of Agriculture
- Pasteur Merieux
- Huazhong University of Science and Technology
- University of Pennsylvania
- Baylor University
- Chang Gung University
- University of London
- Duke University
- Federal University of Health Science of Porto Alegre
- Federal University of Rio Grande do Sul
- Advent Health
- Garvan Institute of Medical Research
- Georgetown University
- Hiroshima University
- Indiana University
- Liverpool John Moores University
- Mahidol University
- Memorial Hermann Health System
- +80 more